<!DOCTYPE html>
<html lang="en">

<head>
  <title>ACS | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/buttons.css" />

  
    <link rel="stylesheet" href="/peripheral_brain/css/diseases.css">
  


  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Condensed" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/site.webmanifest">
  <link rel="mask-icon" href="/peripheral_brain/favicons/safari-pinned-tab.svg" color="#465c8b">
  <link rel="shortcut icon" href="/peripheral_brain/favicons/favicon.ico">
  <meta name="apple-mobile-web-app-title" content="Peripheral Brain">
  <meta name="application-name" content="Peripheral Brain">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/peripheral_brain/favicons/browserconfig.xml">
  <meta name="theme-color" content="#cdcdcd">


  

</head>


<body class="body">
<header id="myHeader" class="myHeader">
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
    <a href="/peripheral_brain/home.html">Home</a>
    <a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a>
    <a href="/peripheral_brain/firstFive">TF5M</a>
    <a href="/peripheral_brain/lab_values">Lab Values</a>
    <a href="/peripheral_brain/formulas">Formulas</a>
    <a href="/peripheral_brain/calculators.html">Calculators</a>
    <a href="/peripheral_brain/search.html">Search</a>
    <a href="javascript:void(0);" class="icon" onclick="openMenu()">&#9776;</a>
  </nav>

  <script>
  function openMenu() {
      var x = document.getElementById("myHeader");
      if (x.className === "myHeader") {
          x.className += " responsive";
      } else {
          x.className = "myHeader";
      }
  }
  </script>
</header>


<h1 class="title">ACS</h1>

<div class="contents twoCol">
  <div class="toc col1">
    
      <ul>
  <li><a href="#dx-">Dx <sup id="fnref:tintinalli"><a href="#fn:tintinalli" class="footnote">1</a></sup><sup>,</sup><sup id="fnref:amsterdam2014"><a href="#fn:amsterdam2014" class="footnote">2</a></sup></a>
    <ul>
      <li><a href="#stemi-dx-criteria">STEMI Dx Criteria</a></li>
    </ul>
  </li>
  <li><a href="#tx-">Tx <sup id="fnref:tintinalli:2"><a href="#fn:tintinalli" class="footnote">1</a></sup><sup>,</sup><sup id="fnref:ogara2013:1"><a href="#fn:ogara2013" class="footnote">4</a></sup></a>
    <ul>
      <li><a href="#stemi-">STEMI <sup id="fnref:tintinalli:3"><a href="#fn:tintinalli" class="footnote">1</a></sup><sup>,</sup><sup id="fnref:ogara2013:2"><a href="#fn:ogara2013" class="footnote">4</a></sup></a></li>
      <li><a href="#nste-acs-">NSTE-ACS <sup id="fnref:amsterdam2014:1"><a href="#fn:amsterdam2014" class="footnote">2</a></sup></a></li>
      <li><a href="#thrombolytic-dosing-">Thrombolytic Dosing <sup id="fnref:lexi"><a href="#fn:lexi" class="footnote">8</a></sup></a></li>
      <li><a href="#thrombolytic-cis-">Thrombolytic CIs <sup id="fnref:ogara2013:3"><a href="#fn:ogara2013" class="footnote">4</a></sup></a></li>
      <li><a href="#post-acs-chronic-therapies">Post-ACS Chronic Therapies</a></li>
    </ul>
  </li>
  <li><a href="#references">References</a></li>
</ul>

    
  </div>

  <div class="content col2">
    <h1 id="dx-">Dx <sup id="fnref:tintinalli"><a href="#fn:tintinalli" class="footnote">1</a></sup><sup>,</sup><sup id="fnref:amsterdam2014"><a href="#fn:amsterdam2014" class="footnote">2</a></sup></h1>

<ul>
  <li><strong>ECG w/i 10min of arrival, then Q15-30min x1hr if not initially
diagnositc</strong></li>
  <li>CXR / Chest CT to r/o thoracic aortic aneurysm / dissection, PE, pneumothorax, PNA, etc</li>
  <li>Serial cTn ASAP then Q3-6hr</li>
  <li><a href="https://qxmd.com/calculate/calculator_168/timi-risk-score-nstemi">TIMI Risk Score</a> for all NSTE-ACS (1pt for each below <sup id="fnref:dipiro"><a href="#fn:dipiro" class="footnote">3</a></sup>)
    <ul>
      <li>≥ 65yo</li>
      <li>Prior Coronary Stenosis ≥ 50%</li>
      <li>ST Depression ≥ 0.5mm</li>
      <li>≥ 2 Anginal events w/i 24hrs</li>
      <li>ASA use w/i 7d</li>
      <li>(+) Cardiac Enzymes</li>
      <li>≥ 3 CAD risk factors
        <ul>
          <li>Smoking</li>
          <li>HTN</li>
          <li>Dyslipidemia</li>
          <li>DM</li>
          <li>FHx of premature CAD or Sudden Cardiac Death</li>
        </ul>
      </li>
      <li><a href="https://qxmd.com/calculate/calculator_262/grace">GRACE Risk Score</a></li>
    </ul>
  </li>
</ul>

<h2 id="stemi-dx-criteria">STEMI Dx Criteria</h2>

<ul>
  <li>ESC/ACC/AHA <sup id="fnref:ogara2013"><a href="#fn:ogara2013" class="footnote">4</a></sup><sup>,</sup><sup id="fnref:thygesen"><a href="#fn:thygesen" class="footnote">5</a></sup>
    <ul>
      <li>ST Elevation in 2 anatomically contiguous leads ≥ 0.1mV at the J-point except V<sub>2</sub>-V<sub>3</sub> (use the following in V<sub>2</sub>-V<sub>3</sub></li>
      <li>Men ≥ 40: ≥ 0.2 mV</li>
      <li>Men &lt; 40: ≥ 0.25 mV</li>
      <li>Women: ≥ 0.15 mV</li>
      <li>New horizontal / down-sloping ST-depression in 2 contiguous leads ≥ 0.05 mV</li>
      <li>T-wave Inversion in 2 contiguous leads ≥ 0.1 mV with prominent R waves or <script type="math/tex">\frac{R}{S} > 1</script></li>
      <li>Definitively new LBBB</li>
    </ul>
  </li>
  <li>In the presence of existing LBBB consider Smith-Modified Sgarbossa
Criteria <sup id="fnref:smith2012-lbbb-stemi"><a href="#fn:smith2012-lbbb-stemi" class="footnote">6</a></sup>
    <ul>
      <li>≥ 3 points ⇒ 98% Likelihood of MI</li>
      <li>ST-elevation ≥1 mm in a lead with upward QRS complex (concordant) - 5 points</li>
      <li>ST-depression ≥1 mm in lead V1, V2, or V3 - 3 points</li>
      <li><script type="math/tex">\frac{\text{ST-change}}{\text{S-wave}} \le -0.25</script> - 2 points</li>
    </ul>
  </li>
  <li>New LAFB and RBBB is concerning for LAD occlusion</li>
  <li>ST-elevation with ST-depression in aVL is highly suspicious for STEMI</li>
  <li>Local ST-depression in V<sub>1</sub>-V<sub>4</sub> is suspicious for isolated posterior infarct</li>
  <li>ST-elevation in aVL with depression in III is suspicious for high lateral MI</li>
  <li>Subtle LAD occlusion vs EBR <sup id="fnref:driver2017"><a href="#fn:driver2017" class="footnote">7</a></sup>
    <ul>
      <li>0.052 x QTc - 0.151 x (QRS voltage in V2) - 0.268 x (R-wave amplitude in V4) + 1.062 x (ST-elevation 60ms after J-point in V3)</li>
      <li>≥ 18.2 ⇒ 88.8% sensitive, 94.7% specific</li>
      <li>≥ 17.75 ⇒ 90.2% sensitive, 90.6% specific</li>
    </ul>
  </li>
</ul>

<p class="caption">Infarction EKG Patterns <sup id="fnref:tintinalli:1"><a href="#fn:tintinalli" class="footnote">1</a></sup></p>

<table>
  <thead>
    <tr>
      <th>Location</th>
      <th>Electrocardiographic Findings</th>
      <th>Artery</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Anteroseptal</td>
      <td>ST-segment elevations in V1, V2, and possibly, V3</td>
      <td>LAD</td>
    </tr>
    <tr>
      <td>Anterior</td>
      <td>ST-segment elevations in V1, V2, V3, and V4</td>
      <td>LAD</td>
    </tr>
    <tr>
      <td>Anterolateral</td>
      <td>ST-segment elevations in V1–V6, I, and aVL</td>
      <td>LAD or LCX</td>
    </tr>
    <tr>
      <td>Lateral</td>
      <td>ST-segment elevations in I and aVL</td>
      <td>LCX</td>
    </tr>
    <tr>
      <td>Inferior</td>
      <td>ST-segment elevations in II, III, and aVF</td>
      <td>RCA or RCX (20%)</td>
    </tr>
    <tr>
      <td>Inferolateral</td>
      <td>ST-segment elevations in II, III, aVF, and V5 and V6</td>
      <td>LCX or RCA or RCX</td>
    </tr>
    <tr>
      <td>True posterior</td>
      <td>Initial R waves in V1 and V2 &gt; 0.04 s and R/S ratio ≥ 1</td>
      <td>LCX</td>
    </tr>
    <tr>
      <td>Right ventricular</td>
      <td>ST-segment elevations in II, III, and aVF and ST elevation in right-side V4</td>
      <td>RCA</td>
    </tr>
  </tbody>
</table>

<h1 id="tx-">Tx <sup id="fnref:tintinalli:2"><a href="#fn:tintinalli" class="footnote">1</a></sup><sup>,</sup><sup id="fnref:ogara2013:1"><a href="#fn:ogara2013" class="footnote">4</a></sup></h1>

<ul>
  <li>Empiric ASA 325mg (chew &amp; swallow) for all pts at risk for AMI w/o CIs</li>
  <li>Nitrates
    <ul>
      <li>Nitro 0.4mg SL Q5min x3 doses</li>
      <li>Nitro IV Start at 10 mcg/min, titrate to 10% reduction in MAP if normotensive, 30% reduction in MAP if hypertensive</li>
      <li>Avoid in RV infarction (d/t dependance on preload for maintaining CO)</li>
      <li>CI w/ PDE-5 Inhibitors w/i 24hr (48hr if Tadalafil)</li>
    </ul>
  </li>
  <li>Supplemental O2 PRN for O2Sat &lt; 90%</li>
  <li>Morphine 2-5mg IV Q5-15min PRN is the preferred method of pain control d/t vasodilatory properties</li>
</ul>

<h2 id="stemi-">STEMI <sup id="fnref:tintinalli:3"><a href="#fn:tintinalli" class="footnote">1</a></sup><sup>,</sup><sup id="fnref:ogara2013:2"><a href="#fn:ogara2013" class="footnote">4</a></sup></h2>

<h3 id="pci-management">PCI Management</h3>

<ul>
  <li>PCI w/i 90min if PCI at facility or w/i 120min for transfer if...
    <ul>
      <li>&lt;12hr from SSx onset</li>
      <li>&lt;12h and CI to fibrinolytics regardless of time limits above</li>
      <li>Cardiogenic shock or acute HF regardless of SSx onset</li>
      <li>Potentially if SSx for 12-24hr</li>
    </ul>
  </li>
  <li>P2Y12 Inhibitor
    <ul>
      <li>Clopidogrel 600mg load then 75mg PO QD x1yr</li>
      <li>Prasugrel 60mg load then 10mg PO QD x1yr (CI w/ prior stroke)</li>
      <li>Ticagrelor 180mg load then 90mg PO BID x1yr (<strong>ASA NTE 100mg w/ ticagrelor</strong>)</li>
    </ul>
  </li>
  <li>Anticoag
    <ul>
      <li>UFH w/ GP IIb/IIIa: 50-70 U/kg bolus targeting aPTT 200-250s</li>
      <li>UFH w/o GP IIB/IIIA: 70-100 U/kg bolus targeting aPTT 250-350s</li>
      <li>Bivalirudin 0.75 mg/kg bolus then 1.75 mg/kg/hr
        <ul>
          <li>Reduce to 1 mg/kg/hr if CrCl &lt; 30</li>
          <li>Preferred over UFH w/ GP IIb/IIIa if high bleed risk</li>
        </ul>
      </li>
    </ul>
  </li>
  <li>GP IIb/IIIa Inhibitors
    <ul>
      <li>Only for select patients</li>
      <li>Abciximab 0.25 mg/kg IVB then 0.125 mcg/kg/min NTE 10 mcg/min</li>
      <li>Tirofiban 25 mcg/kg IVB then 0.15 mcg/kg/min
        <ul>
          <li>CrCl &lt; 30: Reduce rate by 50%</li>
        </ul>
      </li>
      <li>Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min then 180 mcg/kg IVB 10min after 1st IVB
        <ul>
          <li>CrCl &lt; 50: Reduce rate by 50%</li>
          <li>Avoid in pts on HD</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<h3 id="medical-management">Medical Management</h3>

<ul>
  <li>Thrombolytics preferably w/i 30min, should be w/i 1-2hr of presentation if PCI not indicated from above (see dosing below)
    <ul>
      <li>SSx &lt; 12h</li>
      <li>Potentially if SSx for 12-24hr</li>
      <li>Check All CIs to thrombolytics closely</li>
    </ul>
  </li>
  <li>Clopidogrel
    <ul>
      <li>≤ 75yo: 300mg load then 75mg QD x14d-1yr</li>
      <li>&gt; 75yo: 75mg QD x14d-1yr (no load)</li>
    </ul>
  </li>
  <li>Anticoag
    <ul>
      <li>UFH
        <ul>
          <li>Target aPTT 1.5-2x ULN (⇒ 50-70s) x48hr or until revascularization</li>
          <li>60 U/kg IVB NTE 4000 U then</li>
          <li>12 U/kg/hr NTE 1000 U/hr initially titrated to above goal</li>
        </ul>
      </li>
      <li>Enoxaparin
        <ul>
          <li>&lt; 75yo: 30mg <strong>IV</strong> then 15min later 1 mg/kg SubQ Q12H NTE 100mg for the 1st 2 doses</li>
          <li>≥ 75yo: 0.75 mg/kg SubQ Q12H NTE 75mg for the 1st 2 doses</li>
          <li>CrCl &lt; 30: 1 mg/kg Q24H instead</li>
          <li>For duration of stay NTE 8d or until revascularization (unless other indication arises)</li>
        </ul>
      </li>
      <li>Fondaparinux
        <ul>
          <li>2.5mg IVB then 2.5mg SubQ QD starting the next day</li>
          <li>CI if CrCl &lt; 30</li>
          <li>For duration of stay NTE 8d or until revascularization (unless other indication arises)</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<h2 id="nste-acs-">NSTE-ACS <sup id="fnref:amsterdam2014:1"><a href="#fn:amsterdam2014" class="footnote">2</a></sup></h2>

<h3 id="choosing-strategies">Choosing Strategies</h3>

<p><strong>Early Invasive w/i 2hr</strong></p>

<ul>
  <li>Refractory Angina</li>
  <li>Hemodynamic / Electrical Instability</li>
  <li>Sustained VT / VF</li>
  <li>SSx of HF or mitral regurgitation</li>
  <li>Stable pts w/ increased risk of clinical events</li>
  <li>Early-invasive (&lt; 24hr) is better than delayed-invasive if intermediate-high risk</li>
</ul>

<p><strong>Ischemia Guided</strong></p>

<ul>
  <li>Extensive co-morbidities significantly increasing the risk of catheterization</li>
  <li>Acute chest-pain that has a low likelihood of being ACS who are (-) troponin, esp. in women</li>
  <li>TIMI 0-1 or Grace &lt; 109</li>
  <li>Pt / clinician preference in pts w/o high-risk features</li>
</ul>

<p><strong>Early Invasive w/i 24hr</strong></p>

<ul>
  <li>None of above but GRACE &gt; 140</li>
  <li>Changes in Troponin</li>
  <li>New ST depression</li>
</ul>

<p><strong>Delayed Invasive (25-72hr)</strong></p>

<ul>
  <li>None of above but DM</li>
  <li>CrCl &lt; 60</li>
  <li>LVEF &lt; 40%</li>
  <li>PCI w/i 6mo</li>
  <li>Prior CABG</li>
  <li>GRACE 109-140 or TIMI ≥ 2</li>
  <li>Early postinfarction angina</li>
</ul>

<h3 id="ischemia-guided-strategy">Ischemia Guided Strategy</h3>

<ul>
  <li>P2Y12 Inhibitor
    <ul>
      <li>Clopidogrel 600mg load then 75mg PO QD x1yr</li>
      <li>Ticagrelor 180mg load then 90mg PO BID x1yr (<strong>ASA NTE 100mg w/ ticagrelor</strong>, preferred)</li>
    </ul>
  </li>
  <li>Anticoag
    <ul>
      <li>UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI</li>
      <li>Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI</li>
      <li>Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI</li>
    </ul>
  </li>
</ul>

<h3 id="early-invasive-strategy">Early-Invasive Strategy</h3>

<ul>
  <li>P2Y12 Inhibitor
    <ul>
      <li>Clopidogrel 600mg load then 75mg PO QD x1yr</li>
      <li>Ticagrelor 180mg load then 90mg PO BID x1yr (<strong>ASA NTE 100mg w/ ticagrelor</strong>, preferred)</li>
    </ul>
  </li>
  <li>Anticoag
    <ul>
      <li>UFH 60 U/kg load NTE 4000 U then 12 U/kg/h NTE 1000 U/hr titrated to therapeutic aPTT x48hr or until PCI</li>
      <li>Bivalirudin 0.1 mg/kg bolus then 0.25 mg/kg/hr</li>
      <li>Enoxaparin 30mg mg/kg IV loading dose then 1 mg/kg Q12H w/ typical renal adjustments for duration of stay or until PCI</li>
      <li>Fondaparinux 2.5mg SubQ QD for duration of stay or until PCI</li>
    </ul>
  </li>
  <li>GP IIb/IIIa Inhibitors (high-risk only)
    <ul>
      <li>Only for select patients</li>
      <li>Tirofiban 12 mcg/kg IVB then 0.14 mcg/kg/min
        <ul>
          <li>CrCl &lt; 30: Reduce rate and bolus by 50%</li>
        </ul>
      </li>
      <li>Eptifibatide 180 mcg/kg IVB then 2 mcg/kg/min
        <ul>
          <li>CrCl &lt; 50: Reduce rate by 50%</li>
          <li>Avoid in pts on HD</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<h2 id="thrombolytic-dosing-">Thrombolytic Dosing <sup id="fnref:lexi"><a href="#fn:lexi" class="footnote">8</a></sup></h2>

<ul>
  <li>tPA
    <ul>
      <li>15mg IVB over 1-2min then</li>
      <li>0.75mg/kg IV over 30min NTE 50mg then</li>
      <li>0.5 mg/kg IV over 1hr NTE 35mg</li>
      <li>Total dose NTE 100mg</li>
      <li>Wt to achieve max dose: 67kg</li>
    </ul>
  </li>
  <li>Reteplase 10 Units IV over 2min then 10 Units IV over 2min 30min later</li>
  <li>Tenecteplase IV bolus over 5 seconds
    <ul>
      <li>&lt;60 kg: 30 mg</li>
      <li>≥ 60 to &lt;70 kg: 35 mg</li>
      <li>≥ 70 to &lt;80 kg: 40 mg</li>
      <li>≥ 80 to &lt;90 kg: 45 mg</li>
      <li>≥ 90 kg: 50 mg</li>
    </ul>
  </li>
</ul>

<h2 id="thrombolytic-cis-">Thrombolytic CIs <sup id="fnref:ogara2013:3"><a href="#fn:ogara2013" class="footnote">4</a></sup></h2>

<p><strong>Absolute CIs</strong></p>

<ul>
  <li>Any prior ICH</li>
  <li>Known structural cerebral vascular lesion (e.g., arteriovenous malformation)</li>
  <li>Known malignant intracranial neoplasm (primary or metastatic)</li>
  <li>Ischemic stroke within 3 mo</li>
  <li>EXCEPT acute ischemic stroke within 4.5 h</li>
  <li>Suspected aortic dissection</li>
  <li>Active bleeding or bleeding diathesis (excluding menses)</li>
  <li>Significant closed-head or facial trauma within 3 mo</li>
  <li>Intracranial or intraspinal surgery within 2 mo</li>
  <li>Severe uncontrolled hypertension (unresponsive to emergency therapy)</li>
  <li>For streptokinase, prior treatment within the previous 6 mo</li>
</ul>

<p><strong>Relative CIs</strong></p>

<ul>
  <li>History of chronic, severe, poorly controlled hypertension</li>
  <li>Significant hypertension on presentation (SBP &gt; 􏰁180 mm Hg or DBP &gt; 􏰁110 mm Hg)</li>
  <li>History of prior ischemic stroke &gt; 􏰁3 mo</li>
  <li>Dementia</li>
  <li>Known intracranial pathology not covered in absolute contraindications</li>
  <li>Traumatic or prolonged ( &gt; 􏰁10 min) CPR</li>
  <li>Major surgery ( &lt; 􏰂3 wk)</li>
  <li>Recent (within 2 to 4 wk) internal bleeding</li>
  <li>Noncompressible vascular punctures</li>
  <li>Pregnancy</li>
  <li>Active peptic ulcer</li>
  <li>Oral anticoagulant therapy</li>
</ul>

<h2 id="post-acs-chronic-therapies">Post-ACS Chronic Therapies</h2>

<ul>
  <li>Beta-blockers in pts w/o CIs</li>
  <li>ACEIs / ARBs, esp in pts w/ LVEF &lt; 40%</li>
  <li>High-Intensity Statins</li>
  <li>NTG SL PRN</li>
</ul>

<h1 id="references">References</h1>

<div class="footnotes">
  <ol>
    <li id="fn:tintinalli">
      <p>Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. <em>Tintinalli’s Emergency Medicine: A Comprehensive Study Guide</em>. Eight edition. New York: McGraw-Hill Education; 2016. <a href="#fnref:tintinalli" class="reversefootnote">&#8617;</a> <a href="#fnref:tintinalli:1" class="reversefootnote">&#8617;<sup>2</sup></a> <a href="#fnref:tintinalli:2" class="reversefootnote">&#8617;<sup>3</sup></a> <a href="#fnref:tintinalli:3" class="reversefootnote">&#8617;<sup>4</sup></a></p>
    </li>
    <li id="fn:amsterdam2014">
      <p>Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. <em>Journal of the American College of Cardiology</em>. 2014;64(24):e139-e228. doi:<a href="https://doi.org/10.1016/j.jacc.2014.09.017">10.1016/j.jacc.2014.09.017</a> <a href="#fnref:amsterdam2014" class="reversefootnote">&#8617;</a> <a href="#fnref:amsterdam2014:1" class="reversefootnote">&#8617;<sup>2</sup></a></p>
    </li>
    <li id="fn:dipiro">
      <p>DiPiro, JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education, 2017. <a href="#fnref:dipiro" class="reversefootnote">&#8617;</a></p>
    </li>
    <li id="fn:ogara2013">
      <p>O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <em>Journal of the American College of Cardiology</em>. 2013;61(4):e78-e140. doi:<a href="https://doi.org/10.1016/j.jacc.2012.11.019">10.1016/j.jacc.2012.11.019</a> <a href="#fnref:ogara2013" class="reversefootnote">&#8617;</a> <a href="#fnref:ogara2013:1" class="reversefootnote">&#8617;<sup>2</sup></a> <a href="#fnref:ogara2013:2" class="reversefootnote">&#8617;<sup>3</sup></a> <a href="#fnref:ogara2013:3" class="reversefootnote">&#8617;<sup>4</sup></a></p>
    </li>
    <li id="fn:thygesen">
      <p>Thygesen, K, Alpert, JS, Jaffe, AS, Simoons, ML, Chaitman, BR, and White, HD. Third Universal Definition of Myocardial Infarction.16. <a href="#fnref:thygesen" class="reversefootnote">&#8617;</a></p>
    </li>
    <li id="fn:smith2012-lbbb-stemi">
      <p>Smith, SW, Dodd, KW, Henry, TD, Dvorak, DM, and Pearce, LA. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. <em>Annals of Emergency Medicine</em> 2012;60:766–776. <a href="#fnref:smith2012-lbbb-stemi" class="reversefootnote">&#8617;</a></p>
    </li>
    <li id="fn:driver2017">
      <p>Driver, BE, Khalil, A, Henry, T, Kazmi, F, Adil, A, and Smith, SW. A New 4-Variable Formula to Differ- entiate Normal Variant ST Segment Elevation in V2-V4 (Early Repolarization) from Subtle Left Anterior Descending Coronary Occlusion - Adding QRS Amplitude of V2 Improves the Model. <em>Journal of Electrocardiology</em> 2017;50:561–569. <a href="#fnref:driver2017" class="reversefootnote">&#8617;</a></p>
    </li>
    <li id="fn:lexi">
      <p>Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.  Available at:  http://online.lexi.com. <a href="#fnref:lexi" class="reversefootnote">&#8617;</a></p>
    </li>
  </ol>
</div>

  </div>

</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-12-3 <br>
  Last Updated: 2018-12-3</p>
</div>

<footer class="footer menus">
  <nav>
    <div class="footerLinks">
      <a href="/peripheral_brain/home.html">Home</a>
      <a href="/peripheral_brain/index.html">Disclaimer</a>
      <a href="/peripheral_brain/disease_list_old.html">Archived Diseases</a>
    </div>
  </nav>
</footer>


</body>
</html>
